hvsa
Home
Courses
Course Objectives
Programs
CME Credits
Cases and Abstract Submissions
venue and accomodations
HVSA
Directors and Faculty
Videos
Register

 

New York City Conference

Back to 2014 Annual Meeting Abstracts


Redo-aortic Valve Replacement Versus TAVR In Patients With Patent Grafts
Renzo Pessotto, Neal Uren, Andrew Flapan, Sai Prasad, David Northridge, Kirsty Stewart.
Edinburgh Royal Infirmary, Edinburgh, United Kingdom.

OBJECTIVE: Transcatheter aortic valve replacement (TAVR) has been shown to be successful in high risk patients while redo-aortic valve surgery (redo-AVR) in patients with previous coronary artery bypass grafting (CABG) and patent grafts carries a high mortality. To define the best treatment strategy for this cohort of patients, we reviewed our experince with TAVR and redo-AVR at the Edinburgh heart Centre.
METHODS: From January 2011 to December 2013, 86 consecutive patients underwent either TAVR(43) or redo-AVR(43) at our Insitution. All inoperable patients and those considered too high risk for redo-AVR underwent TAVR.Outcomes were prospectively collected.
RESULTS: TAVR patients were significantly older (mean age 80 yrs vs 73) and had a higher logistic euroscore (30.9 vs 9.4). The 30-day mortality
(4.6 % vs 7 %)
and the incidence of debilitating strokes (2.3 vs 4.6 %) were significantly lower in TAVR. Following the procedure, TAVR pts had significantly shorter ITU (2.3 vs 6.2 days) and hospital stays (4.5 vs 18 days)
CONCLUSIONS: TAVR should be considered in all patients with severe AS and patent grafts. Redo-AVR should be considered in younger pts in whom durability of the TAVR might be a concern or whenTAVR is not feasible.


Back to 2014 Annual Meeting Abstracts

     

Home | Courses | Objectives | Program | CME Credit | Cases & Abstracts | Venu & Accomodations | HVSA | Committee & Faculty | Register | Privacy Policy